Q2 Operating income is expected between $460M and $465M.
In the Company’s U.S. dialysis and related lab services segment, the Company expects to report:
Non-acquired treatment growth of 2.1%, with 7,520,587 treatments in second quarter.
Q2 Revenue per treatment of ~$350, an increase of ~$1.60 from Q1 2019.
Second quarter cost per treatment decrease of ~$9 from Q1 2019.
The Company is updating its FY 2019 adjusted operating income guidance to a range of $1.64B to $1.70B from $1.54B to $1.64B.
Final Q2 financial results will be provided on August 1, 2019, at 5:00 p.m. ET.
Share are up 5% premarket on light volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.